Novartis (NVS) Stock Price, News & Analysis

Company Overview

Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia. Its activities also include research and development in areas such as radioligand therapy, cell and gene therapies, and other advanced treatment platforms.

Headquartered in Basel, Switzerland, Novartis serves patients and healthcare providers in markets worldwide. The company was formed in 1996 through the merger of Ciba-Geigy and Sandoz. Novartis completed the spin-off of its generic and biosimilar medicines business, Sandoz, in 2023, allowing it to concentrate on innovative medicines. Vas Narasimhan has served as the company’s chief executive officer since 2018.

Key Stats

• Today's Range: $137.30 to $139.45
• 50-Day Range: $137.52 to $163.27
• 52-Week Range: $121.57 to $170.46
• Volume: 2.94 million shs
• Average Volume: 2.15 million shs
• Market Capitalization: $262.40 billion
• P/E Ratio: 20.74
• Dividend Yield: 2.24%
• Price Target: $141.20
• Consensus Rating: Hold

Novartis Stock Analysis - MarketRank™

Novartis scored higher than 67% of companies evaluated by MarketBeat, and ranked 282nd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Hold

Consensus Rating

Novartis has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 6 buy ratings, 10 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Novartis is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Novartis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.97%

Earnings Growth

Earnings for Novartis are expected to grow by 10.97% in the coming year, from $8.84 to $9.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novartis is 20.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novartis is 20.74, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.79.

Price to Earnings Growth Ratio

Novartis has a PEG Ratio of 2.67. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novartis has a P/B Ratio of 6.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.26% of the float of Novartis has been sold short.

Short Interest Ratio / Days to Cover

Novartis has a short interest ratio ("days to cover") of 3.43, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novartis has recently decreased by 4.71%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novartis pays a meaningful dividend of 2.24%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novartis does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novartis is 46.46%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novartis will have a dividend payout ratio of 31.40% next year. This indicates that Novartis will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.40

News Sentiment

Novartis has a news sentiment score of -0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 36 news articles for Novartis this week, compared to 9 articles on an average week.

Search Interest

17 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 143% compared to the previous 30 days.

MarketBeat Follows

13 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novartis insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.01% of the stock of Novartis is held by insiders.

Percentage Held by Institutions

13.12% of the stock of Novartis is held by institutions.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 9/09/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:NVS
• CIK: 1114448
• Web: www.novartis.com
• Phone: (161) 324-1111
• Fax: 41-61-324-7826
• Employees: 75,267
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Novartis: $141.20
• High Price Target: $180.00
• Low Price Target: $112.00
• Potential Upside/Downside: +2.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.63
• Trailing P/E Ratio: 20.74
• Forward P/E Ratio: 15.56
• P/E Growth: 2.67
• Net Income: $13.98 billion
• Net Margins: 23.29%
• Pretax Margin: 28.34%
• Return on Equity: 38.56%
• Return on Assets: 14.47%

Debt

• Debt-to-Equity Ratio: 0.89
• Current Ratio: 0.86
• Quick Ratio: 0.67

Sales & Book Value

• Annual Sales: $54.53 billion
• Price / Sales: 4.81
• Cash Flow: $10.73 per share
• Price / Cash Flow: 12.82
• Book Value: $22.04 per share
• Price / Book: 6.24

Miscellaneous

• Outstanding Shares: 1,908,150,000
• Free Float: 1,907,961,000
• Market Cap: $262.40 billion
• Optionable: Optionable
• Beta: 0.45